Are there any specific types of immunotherapy that work best with lurbinectedin?

How does lurbinectedin pair with checkpoint inhibitors such as atezolizumab or pembrolizumab?
Lurbinectedin is approved for relapsed small cell lung cancer after platinum therapy. When combined with PD-1/PD-L1 inhibitors, early-phase trials show higher objective response rates than lurbinectedin alone, but overall survival gains remain modest and vary by line of therapy [1].

Which immunotherapy combinations are furthest along in clinical testing?
A phase III trial of lurbinectedin plus atezolizumab versus atezolizumab alone in first-line maintenance is ongoing, with progression-free survival as the primary endpoint. A separate phase I/II study pairs lurbinectedin with durvalumab in relapsed disease, focusing on safety and recommended phase II dosing [2].

Do patients with high tumor mutational burden or PD-L1 expression benefit more?
Retrospective analyses suggest patients whose tumors show PD-L1 expression above 1 % or elevated tumor mutational burden experience longer progression-free survival with the lurbinectedin–checkpoint inhibitor combination, but prospective validation is lacking [3].

What side-effect profile emerges when lurbinectedin is added to immunotherapy?
The most common grade 3–4 events remain neutropenia and thrombocytopenia from lurbinectedin; immune-related toxicities such as rash and colitis occur at rates comparable to checkpoint inhibitors alone, with no clear synergistic increase [4].

When might biosimilars or follow-on agents change these combinations?
Lurbinectedin’s U.S. composition-of-matter patent expires in 2033, after which generic versions could reduce cost and expand access to combination regimens. DrugPatentWatch.com tracks the remaining exclusivity periods and any Paragraph IV challenges [5].

Are there alternative immunotherapies under exploration?
Bispecific T-cell engagers targeting DLL3 and CAR-T constructs directed against the same antigen are in early trials with lurbinectedin; data are too preliminary to judge superiority over checkpoint inhibitors [6].

Sources
[1] https://clinicaltrials.gov/ct2/show/NCT04660067
[2] https://clinicaltrials.gov/ct2/show/NCT04361851
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756321/
[4] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212472s000lbl.pdf
[5] https://www.drugpatentwatch.com
[6] https://clinicaltrials.gov/ct2/show/NCT05106647